ALFA FinderNSE filing, NSE: JUBLPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Jubilant Pharmova Ltd: key numbers
- Share price
- ₹964.65
- Market cap
- ₹15,365 Cr
- Revenue (annual)
- ₹8,280 Cr
- Net profit (annual)
- ₹398.5 Cr
- P/E (TTM)
- 43.6×Sector 43.8×
- Promoter holding
- 47.68%+0.00% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Pharmova Ltd
All →Jubilant Pharmova Q2 FY27 Results: Net Profit ₹31 Cr, Down 74.1% YoY
Jubilant Pharmova Ltd reported revenue from operations of ₹2,370 Cr (+20.5% YoY) and net profit of ₹31 Cr (-74.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹31 Cr · -74.1% YoY
Jubilant Pharmova Business Update
Jubilant Pharmova's subsidiary Jubilant Therapeutics will present preliminary Phase 1 clinical data for JBI-802 at the 68th ASH meeting. A company event on December 14, 2026 will discuss the data.
Jubilant Pharmova Debt & Borrowing: ₹800 Cr
Jubilant Pharmova allotted 80,000 unsecured NCDs worth Rs 800 Crore on a private placement basis. The 8.50% debentures mature in November 2028.
- Value
- ₹800.0 Cr
- Execution
- 3 years (maturity 05 November 2028)
Jubilant Pharmova Board Meeting Date
Jubilant Pharmova has scheduled a board meeting for November 13, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The filing is a Regulation 29 advance intimation only.
Jubilant Pharmova Annual General Meeting
Jubilant Pharmova Ltd has issued a Postal Ballot Notice seeking shareholder approval for the private placement issuance of Non-Convertible Debentures.
Jubilant Pharmova Credit Rating
Jubilant Pharmova received a credit rating of IND AA+/Stable from India Ratings and Research for its proposed Non-Convertible Debentures worth ₹1,400 Crore.
- Value
- ₹1,400 Cr
Other results update announcements
All →Annu Projects Results Update
Annu Projects reported H1 FY27 revenue of ₹35.65 Crore and EBITDA of ₹7 Crore. Unaudited results; order book stands at ₹1,018 Crore.
Frog Innovations Results Update
Frog Innovations reported H1 FY27 revenue up 17.4% to Rs. 645.0 Mn, with profit after tax of Rs. 8.7 Mn. Results highlight a turnaround in profitability.
Ravelcare Results Update
Ravelcare's H1 FY27 unaudited profit after tax nearly doubled to ₹3.84 crore on 20.7% revenue growth. A personalised skincare range is slated for launch by December 2026.
TVS Supply Chain Solutions Results Update
TVS Supply Chain Solutions reported Q2 FY27 revenue up 38% to ₹3,687.2 Cr. PAT rose 124% to ₹36.5 Cr and EBITDA rose 50%.
Vipul Organics Results Update
Vipul Organics reported Q2 standalone revenue up 56.12% YoY and PAT up 22.20%. Half-year revenue rose 47.51%, though a temporary Sayakha ramp-up weighed on margins.
Phoenix Overseas Results Update
Phoenix Overseas reported H1 revenue of Rs. 35,482 lakh, up about 48%. It returned to profit with PAT of Rs. 168 lakh against a prior-year loss.